Deals this week: NanoString Technologies, Ra Medical Systems

20 July 2018 (Last Updated July 20th, 2018 09:30)

NanoString Technologies Inc has raised $50m through an underwritten public offering of shares of its common stock.

NanoString Technologies Inc has raised $50m through an underwritten public offering of shares of its common stock.

The underwriters will receive a 30-day option to buy an additional $7.5m worth of shares.

The company plans to use the funds towards the commercial launch of its digital spatial profiling platform, working capital, and other general corporate purposes.

Wilson Sonsini Goodrich & Rosati has been appointed as the legal advisor to the company for the offering.

Based in the US, NanoString Technologies is engaged in the manufacture of cancer diagnostics tools.

Ra Medical Systems Inc has filed a registration statement with the US Securities and Exchange Commission (SEC) to raise $86.25m through an initial public offering of shares of its common stock.

The underwriters will receive a 30-day option to buy additional shares.

The company plans to use the funds towards product marketing, working capital and other general corporate purposes.

Wilson Sonsini Goodrich & Rosati has been appointed as the legal advisor to the company for the offering.

Based in the US, Ra Medical Systems specialises in the development of laser therapies for dermatology and vascular diseases.

Aziyo Biologics Inc has signed a co-marketing agreement with SurGenTec to supply its bone repair product ViBone.

SurGenTec will market the ViBone product with its patented graft delivery system, GraftGun.

“The company plans to use the funds raised towards its clinical development programme and to strengthen its distribution and strategic partnerships.”

Aziyo Biologics is a biotechnology company engaged in the development of regenerative medicines, while SurGenTec provides technology solutions for the spine and orthopaedic industry.

Both the companies involved in the transaction are based in the US.

Creo Medical Group plc has raised £48.5m ($64.06m) through the private placement of 38.8 million shares priced at £1.25 ($1.65) a share. The financing was provided by Cenkos Securities plc.

Based in the UK, Creo Medical specialises in the development of innovative medical devices.

The company plans to use the funds raised towards its clinical development programme and to strengthen its distribution and strategic partnerships.

Cellenion has signed a co-marketing agreement with Miltenyi Biotec to provide cost-effective solutions to accelerate the development of monoclonal cell lines.

Cellenion and Miltenyi Biotec will improve the development process through the combined use of the cellenONE X1 single-cell deposition unit and the MACSQuant Tyto Cell Sorter.

Based in France, Cellenion is engaged in the development of controlled cell dispensing technologies and a subsidiary of SCIENION, while Miltenyi Biotec is a German medical device company.

The deal enables the two companies to co-develop and market monoclonal antibodies.

Cagent Vascular LLC has raised $11.87m through a series B funding round from two investors.

The funding round also included the participation of Balestier Investments, Ben Franklin Technology Partners1, and Synergy Ventures.

Based in the US, Cagent Vascular is engaged in the development of angioplasty balloons that are produced using proprietary serration technology.

The company plans to use the funds towards the commercial launch of its product Serranator Alto and its family of serration balloon catheters.